Shopping Cart 0
Cart Subtotal
AED 0

Iron Deficiency Anemia - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020

Details

Iron Deficiency Anemia-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia-Pipeline Review, H1 2019, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape.

Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Iron Deficiency Anemia-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Iron Deficiency Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 3, 3, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia (Hematological Disorders).

- The pipeline guide reviews pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Iron Deficiency Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Iron Deficiency Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Iron Deficiency Anemia (Hematological Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Iron Deficiency Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Iron Deficiency Anemia-Overview

Iron Deficiency Anemia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Iron Deficiency Anemia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Iron Deficiency Anemia-Companies Involved in Therapeutics Development

Akebia Therapeutics Inc

Iron4u Aps

Novartis AG

Panion & Bf Biotech Inc

Pharmacosmos AS

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Vifor Pharma Ltd

Iron Deficiency Anemia-Drug Profiles

AKB-5343-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSJ-137-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Replace Iron for Iron Deficiency Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ferric bepectate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric carboxymaltose-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric maltol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric pyrophosphate citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hinokitiol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iron isomaltoside-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Activate Erythroferrone for Iron Deficiency Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-080-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PT-30-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Iron Deficiency Anemia-Dormant Projects

Iron Deficiency Anemia-Product Development Milestones

Featured News & Press Releases

Jan 29, 2019: Positive results of long-term phase of AEGIS-CKD study further demonstrate the benefits of Feraccru

Jan 24, 2019: Shield Therapeutics: Business and trading update

Dec 13, 2018: Shield Therapeutics announces the US new drug application PDUFA date for Feraccru

Dec 10, 2018: Rockwell Medical appoints new Vice President, Operations

Dec 06, 2018: Clinical trial sheds new light on potential risk associated with intravenous iron treatment

Dec 05, 2018: Shield Therapeutics notes UK launch of Feraccru by Norgine

Dec 04, 2018: New study demonstrates significant difference between Iron Isomaltoside and Ferric Carboxymaltose on hypophosphatemic effects in a controlled, randomized clinical investigation

Dec 03, 2018: Shield Therapeutics announces the new drug application for Feraccru has been accepted for filing and review by the FDA

Oct 12, 2018: Rockwell Medical provides update on IV Triferic

Oct 01, 2018: Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru for the treatment of iron deficiency with the US Food and Drug Administration (FDA)

Sep 13, 2018: Shield reports completion of recruitment to AEGIS Head to Head Study (AEGIS-H2H) comparing Feraccru with ferric carboxymaltose

Sep 06, 2018: Monoferric receives marketing approval from Health Canada

Jun 28, 2018: Shield Reports Recently Presented Supportive Data from Real-world Clinical use of Feraccru (Ferric Maltol)

Jun 14, 2018: Shield reports positive top-line results from its AEGIS-PAED PK Paediatric Phase I Pharmacokinetics study of Feraccru (Ferric Maltol) in subjects with iron deficiency

May 02, 2018: Rockwell Medical Announces Triferic Presentations at the 2018 International Congress on Peritoneal Dialysis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Iron Deficiency Anemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Iron Deficiency Anemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Iron Deficiency Anemia-Pipeline by Akebia Therapeutics Inc, H1 2019

Iron Deficiency Anemia-Pipeline by Iron4u Aps, H1 2019

Iron Deficiency Anemia-Pipeline by Novartis AG, H1 2019

Iron Deficiency Anemia-Pipeline by Panion & Bf Biotech Inc, H1 2019

Iron Deficiency Anemia-Pipeline by Pharmacosmos AS, H1 2019

Iron Deficiency Anemia-Pipeline by Pieris Pharmaceuticals Inc, H1 2019

Iron Deficiency Anemia-Pipeline by Rockwell Medical Inc, H1 2019

Iron Deficiency Anemia-Pipeline by Shield Therapeutics Plc, H1 2019

Iron Deficiency Anemia-Pipeline by Vifor Pharma Ltd, H1 2019

Iron Deficiency Anemia-Dormant Projects, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Iron Deficiency Anemia Therapeutic Products under Development, Key Players in Iron Deficiency Anemia Therapeutics, Iron Deficiency Anemia Pipeline Overview, Iron Deficiency Anemia Pipeline, Iron Deficiency Anemia Pipeline Assessment


Companies

Akebia Therapeutics Inc

Iron4u Aps

Novartis AG

Panion & Bf Biotech Inc

Pharmacosmos AS

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Vifor Pharma Ltd

Company Profile

Company Profile Title

Iron Deficiency Anemia-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Iron Deficiency Anemia-Pipeline Review, H1 2019, provides an overview of the Iron Deficiency Anemia (Hematological Disorders) pipeline landscape.

Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cells. When body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Iron Deficiency Anemia-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Iron Deficiency Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 3, 3, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia (Hematological Disorders).

- The pipeline guide reviews pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Iron Deficiency Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Iron Deficiency Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Iron Deficiency Anemia (Hematological Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Iron Deficiency Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Iron Deficiency Anemia-Overview

Iron Deficiency Anemia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Iron Deficiency Anemia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Iron Deficiency Anemia-Companies Involved in Therapeutics Development

Akebia Therapeutics Inc

Iron4u Aps

Novartis AG

Panion & Bf Biotech Inc

Pharmacosmos AS

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Vifor Pharma Ltd

Iron Deficiency Anemia-Drug Profiles

AKB-5343-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSJ-137-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Replace Iron for Iron Deficiency Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ferric bepectate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric carboxymaltose-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric maltol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ferric pyrophosphate citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hinokitiol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iron isomaltoside-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Activate Erythroferrone for Iron Deficiency Anemia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-080-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PT-30-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Iron Deficiency Anemia-Dormant Projects

Iron Deficiency Anemia-Product Development Milestones

Featured News & Press Releases

Jan 29, 2019: Positive results of long-term phase of AEGIS-CKD study further demonstrate the benefits of Feraccru

Jan 24, 2019: Shield Therapeutics: Business and trading update

Dec 13, 2018: Shield Therapeutics announces the US new drug application PDUFA date for Feraccru

Dec 10, 2018: Rockwell Medical appoints new Vice President, Operations

Dec 06, 2018: Clinical trial sheds new light on potential risk associated with intravenous iron treatment

Dec 05, 2018: Shield Therapeutics notes UK launch of Feraccru by Norgine

Dec 04, 2018: New study demonstrates significant difference between Iron Isomaltoside and Ferric Carboxymaltose on hypophosphatemic effects in a controlled, randomized clinical investigation

Dec 03, 2018: Shield Therapeutics announces the new drug application for Feraccru has been accepted for filing and review by the FDA

Oct 12, 2018: Rockwell Medical provides update on IV Triferic

Oct 01, 2018: Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru for the treatment of iron deficiency with the US Food and Drug Administration (FDA)

Sep 13, 2018: Shield reports completion of recruitment to AEGIS Head to Head Study (AEGIS-H2H) comparing Feraccru with ferric carboxymaltose

Sep 06, 2018: Monoferric receives marketing approval from Health Canada

Jun 28, 2018: Shield Reports Recently Presented Supportive Data from Real-world Clinical use of Feraccru (Ferric Maltol)

Jun 14, 2018: Shield reports positive top-line results from its AEGIS-PAED PK Paediatric Phase I Pharmacokinetics study of Feraccru (Ferric Maltol) in subjects with iron deficiency

May 02, 2018: Rockwell Medical Announces Triferic Presentations at the 2018 International Congress on Peritoneal Dialysis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Iron Deficiency Anemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Iron Deficiency Anemia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Iron Deficiency Anemia-Pipeline by Akebia Therapeutics Inc, H1 2019

Iron Deficiency Anemia-Pipeline by Iron4u Aps, H1 2019

Iron Deficiency Anemia-Pipeline by Novartis AG, H1 2019

Iron Deficiency Anemia-Pipeline by Panion & Bf Biotech Inc, H1 2019

Iron Deficiency Anemia-Pipeline by Pharmacosmos AS, H1 2019

Iron Deficiency Anemia-Pipeline by Pieris Pharmaceuticals Inc, H1 2019

Iron Deficiency Anemia-Pipeline by Rockwell Medical Inc, H1 2019

Iron Deficiency Anemia-Pipeline by Shield Therapeutics Plc, H1 2019

Iron Deficiency Anemia-Pipeline by Vifor Pharma Ltd, H1 2019

Iron Deficiency Anemia-Dormant Projects, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Iron Deficiency Anemia Therapeutic Products under Development, Key Players in Iron Deficiency Anemia Therapeutics, Iron Deficiency Anemia Pipeline Overview, Iron Deficiency Anemia Pipeline, Iron Deficiency Anemia Pipeline Assessment


Companies

Akebia Therapeutics Inc

Iron4u Aps

Novartis AG

Panion & Bf Biotech Inc

Pharmacosmos AS

Pieris Pharmaceuticals Inc

Rockwell Medical Inc

Shield Therapeutics Plc

Vifor Pharma Ltd